Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02113982 · OUTCOME

Bridge to SCT in First-line BPDCN, R/R BPDCN and AML

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia · Source last updated 2024-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of evaluable patients
Interval / dispersion
Not reported
Time frame
at pre-defined intervals up to achievement of outcome enabling an SCT for a period, up to 5 years

What was measured

Bridge to Stem Cell Transplant (SCT) defined as the percentage of patients who received SCT subsequent to achieving an Investigator-determined outcome from Tagraxofusp that was deemed by the Investigator to enable an SCT

Analysis population: Efficacy population including evaluable patients treated at 12 μg/kg/day in the first-line BPDCN, R/R BPDCN and AML

Groups in this outcome

First-line BPDCN

First-line BPDCN patients enrolled across stages

R/R BPDCN

R/R BPDCN patients enrolled across stages

Acute Myeloid Leukemia

AML patients enrolled in stages 1 and 2

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
First-line BPDCN65
R/R BPDCN19
Acute Myeloid Leukemia36

Reported measurements

Source class 1
Values in percentage of evaluable patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
First-line BPDCN32.3Not reportedNot reportedNot reportedNot reported
R/R BPDCN5.3Not reportedNot reportedNot reportedNot reported
Acute Myeloid Leukemia3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        32.3
      2. group Id
        OG001
        value
        5.3
      3. group Id
        OG002
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      65
    2. group Id
      OG001
      value
      19
    3. group Id
      OG002
      value
      36
    units
    Participants
description
Bridge to Stem Cell Transplant (SCT) defined as the percentage of patients who received SCT subsequent to achieving an Investigator-determined outcome from Tagraxofusp that was deemed by the Investigator to enable an SCT
groups
  1. description
    First-line BPDCN patients enrolled across stages
    id
    OG000
    title
    First-line BPDCN
  2. description
    R/R BPDCN patients enrolled across stages
    id
    OG001
    title
    R/R BPDCN
  3. description
    AML patients enrolled in stages 1 and 2
    id
    OG002
    title
    Acute Myeloid Leukemia
param Type
NUMBER
population Description
Efficacy population including evaluable patients treated at 12 μg/kg/day in the first-line BPDCN, R/R BPDCN and AML
reporting Status
POSTED
time Frame
at pre-defined intervals up to achievement of outcome enabling an SCT for a period, up to 5 years
title
Bridge to SCT in First-line BPDCN, R/R BPDCN and AML
type
SECONDARY
unit Of Measure
percentage of evaluable patients

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice